ChemicalBook >> journal list >> Cell reports >>article
Cell reports

Cell reports

IF: 7.5
Download PDF

Lipid-coated nanoparticles enhance the delivery of bacterial virulence factors as a potent toxoid vaccine platform against bacterial infections.

Published:24 June 2025 DOI: 10.1016/j.celrep.2025.115786 PMID: 40482034
Deli Zhuge, Yingnan Xiao, Yunxuan Huang, Yutong Zhong, Xueying Sun, Jing Wu, Shuangshuang Liu, Hui Liang, Weian Mao, Yuan Yang, Yijing Lin, Haonan Wang, Xuewei Yang, Xufei Zhang, Wenjie Sun, Caixia Liu, Yingzheng Zhao, Mengchun Chen, Yijie Chen

Abstract

Antivirulence vaccination represents a promising strategy for infection prevention, but achieving both safety and efficacy in toxoid vaccine preparation remains a challenge. Cell membrane-based nanotoxoids offer a safe delivery platform for bacterial virulence factors in antivirulence vaccination, but limited absorption capacity hampers their efficacy. Here, we develop a lipid-based toxoid vaccine platform, PSV-CNP, comprising a CpG-loaded polymeric core coated with phosphatidylcholine/sphingomyelin (PS) liposomes enriched with bacterial virulence factors. By enhancing virulence factor absorption, PSV-CNP elicits robust humoral immunity. In mice, it provides long-lasting protection against methicillin-resistant Staphylococcus aureus (MRSA) and clinically isolated S. aureus (CI-SA), even under immunosuppression. In Bama pigs, PSV-CNP induces strong immune responses and prevents MRSA and CI-SA invasion. Furthermore, PS-liposomes efficiently absorb virulence factors from Pseudomonas aeruginosa (PA), conferring protection against PA infections. This study establishes PS-coated nanoparticles as a broadly applicable, safe, and effective antivirulence toxoid vaccine platform.

Similar articles

IF:5.6

Enrofloxacin—The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?

International Journal of Molecular Sciences Łukasz Grabowski, Lidia Gaffke,etc Published: 26 March 2022
IF:13

Gatifloxacin: a review of its use in the treatment of bacterial infections in the US.

Drugs Susan J Keam, Katherine F Croom,etc Published: 1 January 2005
IF:13

Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.

Drugs Caroline M Perry, Lesley J Scott,etc Published: 1 January 2004